Data gathered: January 14
AI Stock Analysis - Vanda Pharmaceuticals (VNDA)
Analysis generated April 18, 2024. Powered by Chat GPT.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of central nervous system disorders. Their work includes treatments for schizophrenia, jet lag, non-24-hour sleep-wake disorder, and other health conditions. They have marketed products and a pipeline of clinical-stage candidates, positioning the company for potential long-term growth and investment interest.
Stock Alerts - Vanda Pharmaceuticals (VNDA)
 |
Vanda Pharmaceuticals | January 11 Web Traffic is down by 72.1% over the last month. |
|
Vanda Pharmaceuticals | January 8 AI Score is up by 21.2% in the last couple of days. |
|
Vanda Pharmaceuticals | January 8 Price is down by -5.2% in the last 24h. |
|
Vanda Pharmaceuticals | December 17 Employee Rating is up by 6.5% over the last month. |
Alternative Data for Vanda Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 80 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 17,000 | Sign up | Sign up | Sign up |
| Employee Rating | 66 | Sign up | Sign up | Sign up |
| Google Trends | 27 | Sign up | Sign up | Sign up |
| Patents | 121 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,339 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,051 | Sign up | Sign up | Sign up |
| Twitter Mentions | 5 | Sign up | Sign up | Sign up |
| News Mentions | 2 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 30 | Sign up | Sign up | Sign up |
| Linkedin Employees | 410 | Sign up | Sign up | Sign up |
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
| Price | $4.38 |
| Target Price | Sign up |
| Volume | 459,540 |
| Market Cap | $315M |
| Year Range | $4.38 - $6.5 |
| Dividend Yield | 0% |
| PE Ratio | 126 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by Analysts at StockNews.comJanuary 13 - ETF Daily News |
 |
Critical Analysis: Novo Nordisk A/S (NYSE:NVO) versus Vanda Pharmaceuticals (NASDAQ:VNDA)January 12 - ETF Daily News |
 |
Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?January 6 - Yahoo |
|
Geode Capital Management LLC Buys 94,870 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)January 4 - ETF Daily News |
|
Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated by Analysts at StockNews.comDecember 27 - ETF Daily News |
|
Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Buy Rating from HC WainwrightDecember 24 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 48M | 42M | 5.7M | -5.3M | -9.2M | -0.090 |
| Q2 '24 | 50M | 44M | 6.5M | -4.5M | -8.3M | -0.080 |
| Q1 '24 | 47M | 36M | 12M | -4.1M | -7.2M | -0.072 |
| Q4 '23 | 45M | 28M | 17M | -2.4M | -6.1M | -0.040 |
| Q3 '23 | 39M | 28M | 11M | 140,000 | -5.6M | 0.002 |
Insider Transactions View All
| Mitchell Stephen Ray filed to sell 44,857 shares at $5.2. November 18 '24 |
| Moran Kevin Patrick filed to sell 228,763 shares at $5.9. July 29 '24 |
| Birznieks Gunther filed to sell 313,569 shares at $4.1. March 6 '24 |
| Moran Kevin Patrick filed to sell 231,014 shares at $4.2. March 6 '24 |
| Wijkstrom Joakim filed to sell 129,789 shares at $4.2. March 6 '24 |
Similar companies
Read more about Vanda Pharmaceuticals (VNDA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Vanda Pharmaceuticals?
The Market Cap of Vanda Pharmaceuticals is $315M.
What is Vanda Pharmaceuticals' PE Ratio?
As of today, Vanda Pharmaceuticals' PE (Price to Earnings) ratio is 126.
What is the current stock price of Vanda Pharmaceuticals?
Currently, the price of one share of Vanda Pharmaceuticals stock is $4.38.
How can I analyze the VNDA stock price chart for investment decisions?
The VNDA stock price chart above provides a comprehensive visual representation of Vanda Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Vanda Pharmaceuticals shares. Our platform offers an up-to-date VNDA stock price chart, along with technical data analysis and alternative data insights.
Does VNDA offer dividends to its shareholders?
As of our latest update, Vanda Pharmaceuticals (VNDA) does not offer dividends to its shareholders. Investors interested in Vanda Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Vanda Pharmaceuticals?
Some of the similar stocks of Vanda Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.